Peter Jacob Mohr MD
Adult Congenital Heart Disease, Interventional Cardiology
Physician
Join to View Full Profile
6600 Bruceville RdMob 3; 1st FloorSacramento, CA 95823
Phone+1 916-688-2315
Fax+1 314-362-4278
Dr. Mohr is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Scripps Clinic/Scripps Green HospitalFellowship, Interventional Cardiology, 2010 - 2011
SSM Health/Saint Louis University School of MedicineFellowship, Cardiovascular Disease, 2007 - 2010
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
Tufts University School of MedicineClass of 2003
Certifications & Licensure
CA State Medical License 2010 - 2026
American Board of Internal Medicine Cardiovascular Disease- American Board of Internal Medicine Interventional Cardiology
National Board of Physicians and Surgeons Cardiovascular Disease- National Board of Physicians and Surgeons Interventional Cardiology
Clinical Trials
- Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Start of enrollment: 2003 Nov 01
- Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Start of enrollment: 2001 Sep 01
- CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy Start of enrollment: 2008 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- BRAFMetastatic Melanoma Journey: A Perspective from a Patient and his Oncologist.Carsten Finke, Peter Mohr
Advances in Therapy. 2024-07-01 - 25 citationsCorrelation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective mult...Jan-Malte Placke, Mona Kimmig, Klaus Griewank, Rudolf Herbst, Patrick Terheyden
Ebiomedicine. 2023-10-01 - 8 citationsCharacterisation and outcome of RAC1 mutated melanoma.Georg C Lodde, Philipp Jansen, Rudolf Herbst, Patrick Terheyden, Jochen Utikal
European Journal of Cancer. 2023-04-01
Press Mentions
Bristol Myers Squibb Receives European Commission Approval for Opdivo (Nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC MelanomaAugust 23rd, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
